RET Inhibitors in Non-Small-Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Rearranged during transfection (RET) gene rearrangements are oncogenic drivers in 1-2% of non-small-cell lung cancer (NSCLC) cases.
• These rearrangements lead to constitutive activation of cell proliferation and survival pathways.
• RET-rearranged NSCLC is often associated with non-smoking history, brain metastasis, and low immune infiltrate.

Purpose of the Study:

• To review the clinical significance and therapeutic landscape of RET rearrangements in NSCLC.
• To evaluate the efficacy and tolerability of targeted therapies, particularly selective RET inhibitors.

Main Methods:

• Review of clinical trial data and literature on RET-rearranged NSCLC.
• Analysis of outcomes for multi-kinase inhibitors and selective RET inhibitors.

Main Results:

• Early multi-kinase inhibitors showed variable results in RET-rearranged NSCLC.
• Selective RET inhibitors (selpercatinib, pralsetinib) demonstrated superior efficacy and tolerability in phase II studies.
• These agents are approved for metastatic RET fusion-positive NSCLC.

Conclusions:

• Selective RET inhibitors represent a significant advancement in treating RET-rearranged NSCLC.
• Ongoing phase III trials will further define the role of these agents in first-line therapy.